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Abstract
Background: Phambili, the Merck (MRK)-Adenovirus Type 5 (Ad5) HIV-1 gag/pol/nef subtype B vaccine study, conducted in
South Africa, suspended enrollment and vaccination when companion study, Step, was found non-efficacious. Although the
vaccine did not prevent HIV-1 infection or lower viral-load setpoint, immune responses recognized clades B and C HIV-1
subtypes. We investigated predictors of the vaccine-induced antigen-specific immune responses.
Methods: Vaccine-induced immunogenicity was ascertained by interferon-c ELISpot assays on the first 186 enrolled
participants receiving two vaccinations. Analyses, stratified by study arm/sex, were performed on baseline demographics
[sex, age, Body Mass Index (BMI), site, Adenovirus Type-5 (Ad5) titer, Herpes Simplex Virus Type-2 (HSV2) status, heavy
drinking]. Multivariate logistic regression determined predictors.
Results: Of the 186 participants, 53.7% (n = 100) were female, median BMI was 22.5 [IQR: 20.4–27.0], 85.5% (n = 159) were
Ad5 seropositive, and 18.8% (n = 35) drank heavily. All vaccine recipients responded to both clade B (n = 87; 47%) and/or C
(n = 74; 40%), p = 0.17. In multivariate analysis, female sex [Adjusted Odds Ratio (AOR): 6.478; p = 0.0159], overweight/obese
BMI (AOR: 0.186; p = 0.0452), and heavy drinking (AOR: 0.270; p = 0.048) significantly predicted immune response to clade C
for any antigens. A marginally significant predictor of clade C-pol antigen was female sex (AOR: 3.182; p = 0.0500).
Conclusions: Sex, BMI, and heavy drinking affected vaccine-induced HIV-1 specific immune responses to clade C antigens.
The role of female sex and overweight/obese BMI boosting and suppressing vaccine-induced HIV-1 specific immune
responses, respectively, requires elucidation, including any effect on HIV vaccine efficacy, especially in the era of colliding
epidemics (HIV and obesity).
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Phambili (HVTN 503) was a Phase IIb HIV vaccine efficacy
study conducted in South Africa. It investigated the Merck
(MRK)-Adenovirus type-5 (Ad5) HIV-1 clade B trivalent HIV
vaccine, which contains recombinant Ad5 (rAd5) vectors express-
ing clade B gag, pol, and nef epitopes [1–3]. The trial suspended
enrollment and vaccination in September 2007 when the interim
efficacy analysis from its companion study, Step (HVTN 502/
MRK 023), conducted in North America, South America, the
Caribbean, and Australia, crossed pre-specified futility boundaries
for efficacy while still in its vaccination period [1],[3]. Although
the vaccine neither prevented HIV-1 infection nor lowered viral
load setpoint, immune responses recognized clades B and C HIV-
1 subtypes [3].
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Vaccine-induced immune responses to HIV-1 may not neces-
sarily equate to protection or risk. It is uncertain which immune
responses are required for protection against HIV infection or
controlling viremia [4]. Most vaccines combating viruses stimulate
production of antigen-specific memory B- and/or cytotoxic T
lymphocytes (CTL) which can rapidly multiply upon exposure to
targeted pathogens, controlling infection. Ad5 is the best-studied
serotype of adenoviral vaccine vectors [5]. Replication-defective
Ad5 viruses are potential HIV vaccine vectors based on their
ability to stimulate anti-HIV CTL responses associated with killing
HIV-infected cells following initial infection [5]. Phase 1 clinical
studies found Ad5 vector-based vaccines to be among the most
immunogenic of cell-mediated immune vaccines [6], [7]. Gag, pol,
and nef epitopes are known to elicit high CTL responses, helping
control HIV; gag proteins create structural HIV membrane
components, and pol and nef proteins support viral replication [8].
The MRK-Ad5 HIV-1 gag/pol/nef vaccine, consisting of a
1:1:1 mixture of these three vectors, expresses the gag gene from
the HIV-1 strain CAM-1, the pol gene from HIV-1 strain IIIB,
and the nef gene from HIV-1 strain JR-FL. These genes are
representative of the respective consensus clade B sequences. Each
vector expresses one of the three genes inserted into the adenoviral
E1 region. This trivalent vaccine presently consists of mixtures of
the three individual vectors. The MRK-Ad5 HIV-1 gag/pol/nef
trivalent vaccine elicited gag-specific immune responses compara-
ble to those elicited by the Ad5 and MRK-Ad5 HIV-1 gag
monovalent vaccines, but the responses elicited by the trivalent
vaccine were broader since responses were also seen to both pol
and nef peptides. Broader responses should make immunological
escape less likely to occur. The MRK-Ad5 vaccine did stimulate
CTL responses in a large proportion of vaccine-recipients, but
failed to prevent HIV acquisition and control HIV levels in
participants who became infected during the trial [3]. It remains
unknown if the MRK-Ad5 vaccine efficacy failure was due to the
vaccine regimen or whether CTL properties simply are not useful
correlates of immune protection [4].
Another challenge in developing an effective HIV vaccine is the
paucity of data to elucidate the innate predictors affecting immune
responses and to understand how this could affect vaccine efficacy
[9]. Previous studies of viral vector or recombinant subunit
vaccines provide evidence of socio-demographic predictors of
immune response, such as age and obesity [10–14]. Influenza
vaccinations with inactivated virus are less effective, eliciting poor
immune responses, in both young children and the elderly, due to
either undeveloped or less-proficient, aged immune systems,
respectively [10–12]. One study showed only 17% of 153
participants aged 65–98 years receiving a trivalent influenza
vaccine generated increased antibody titers to all three vaccine
components, and 46% of those immunized failed to respond to all
three of the vaccine elements [10]. Obesity, as measured by a
higher weight-height index, and older age were predictors of poor
immunogenic response to the Hepatitis B plasma vaccine [13]. A
higher dosage series of the Hepatitis B vaccine induced greater
protective levels of antibodies in 94–100% of healthy infants,
children, and adolescents; yet immune responses for the same
three-dose vaccination series were lower for older persons (adults
aged 40–60 years, .90% protection; adults aged 60+ years, 65–
75% protection) [14].
Phambili participant risk behavior at baseline or during the
study served as unlikely explanations for the increased rate of
HIV-1 infections seen in vaccine recipients [15]. It is not yet
known if there are innate, influential factors affecting the Phambili
vaccine-induced immune response. We investigate predictors
associated with the MRK-Ad5 vaccine-specific T-cell immune
response for HIV-1 clade B and clade C amongst South African
participants in an attempt to further improve upon future HIV
vaccine candidates.
Methods
Study Design of Phambili and Participants
The methods of Phambili have been previously described [3]. In
summary, Phambili was a multicenter, double-blind, randomized,
placebo-controlled clinical trial conducted between 24 January
and 19 September, 2007. The interim efficacy analysis report
found the study vaccine elicited an immune response recognizing
two subtypes of HIV-1 (clade B and C) but was not deemed
efficacious [3]. The clinical trial was approved by the relevant
regulatory bodies in South Africa and the United States.
Participants provided written informed consent in English or their
local language [3]. The trial was registered in clinicaltrials.gov
(NCT00413725) and the South Africa National Health Research
Database (DOH-27-0207-1539) [3].
Phambili was conducted at five sites: Soweto, Cape Town,
Klerksdorp, eThekwini, and Medunsa. Eligible individuals were
consenting, healthy, HIV-1-uninfected men and women aged 18–
35 years, sexually active within six months of enrollment. Women
could not be pregnant or breastfeeding, and agreed to use two
methods of contraception [3]. Heavy drinking in the previous six
months, an HIV-1 risk behavior, was assessed at screening [3].
Participant Procedures
Of 1428 individuals screened, 801 were randomized to receive
either vaccine or placebo (400 vaccine recipients, 401 placebo-
controls) [3]. Participants were randomized 1:1 between vaccine
and placebo, using blocked randomization stratified across sites
and sex [3].
Vaccines were injected intramuscularly at 0, 1, 6 months, with
1.561010 adenovirus genomes per mL of study product or 1.0 mL
solution of vaccine diluent without Ad5 vector as placebo [3].
Participant serum samples were collected at enrollment for
neutralizing Ad5 (NAd5) antibody titers [3] and herpes simplex
virus type-2 (HSV-2) serology [3]. The HSV-2 antibody is a
marker of previous exposure to a common sexually transmitted
infection that has been associated with HIV-acquisition, especially
in urban African populations [16]. Clinical assessments were
performed and HIV-1 prevention interventions were provided
throughout the trial. HIV-1 testing was conducted at first
vaccination, week 12, week 30, at unmasking, and every six
months thereafter during the follow-up period with an algorithm
determining true infection from vaccine-induced seropositivity
[3], [17].
Immunological Tests
Since interferon-c (IFN-c) ELISpot was the primary immuno-
genicity assay used for early phase vaccine testing, it remained as
such for this study. At the Fred Hutchinson Research Center
HVTN laboratory, vaccine immunogenicity was assessed on a
subset of participants using previously cryopreserved peripheral-
blood mononuclear cells (PBMC) obtained by venipuncture at
week 8, four weeks post second vaccination [3]. A validated IFN-c
ELISpot assay assessed the ex-vivo T-cell responses using PBMC
stimulated overnight with two panels of peptide pools from HIV-1
clades B and C, using standard protocols [1]. There were peptide
pools for two clades because the vaccine encoded clade B antigens
while the study was conducted in a clade C region; there was also
interest in the ability of the vaccine to elicit cross-protective clade
C responses. The synthetic clade B peptide pools contained
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vaccine-matched proteins – one gag, one nef, and two pol pools.
Since vaccine-matched peptides were not an option to evaluate
clade C responses, the clade C peptide pools contained potential
T-cell epitopes (PTE) of common clade C peptides from Southern
African isolates – two gag, one nef, and three pol pools [3].
The assay was conducted for the first 186 participants enrolled
(93 vaccine recipients, 93 placebo-controls) who were HIV-1
antibody negative at the week 12 visit, received the first
vaccination and then second injection within the day 28 visit
window (days 19–42), and whose thawed PBMC had $66%
viability [3]. Specimens included in the statistical analysis met the
following criteria: mean of the medium-only wells # six
background-subtracted spot forming cells (SFCs)/200,000 PBMC;
mean for the three positive control wells $400 SFCs/200,000
PBMC; mean for the negative control wells #20 SFCs/200,000
PBMC; and results existed for at least four of the six negative
control wells [3]. Lab personnel were blinded to the treatment arm
assignment.
Statistical Methodology
Statistical analyses were performed with SAS (version 9.3, SAS
Institute, Cary, NC). The ELISpot assay analysis methodology was
previously described [3].
BMI (measured as: weight (in kilograms) / [height (in meters)]2)
was categorized as the following: underweight ,18.5; normal
18.5–24.9; overweight 25.0–29.9; and obese .29.9. NAd5 titer
was defined as detectable ($18 units) and undetectable (,18
units). Heavy drinking was defined per protocol as having more
than five drinks per day on at least ten days within the past six
months.
Baseline demographical information (study site, age, BMI, Ad5
titer, HSV-2 status, and heavy drinking) for the 186 immunoge-
nicity participants was presented as frequencies for categorical
variables and descriptively for continuous variables, stratified by
study arm and sex. Chi-squared analyses compared categorical
variables. BMI was evaluated by sex and across sites using the
Kruskall-Wallis non-parametric test.
Univariate and multivariate predictors of clades B and C
immune responses for both any and clade-specific antigens were
Table 1. Baseline Demography of Immunogenicity Participants at Enrollment.
Vaccine Arm (n = 93) Placebo Arm (n = 93)
Males Females Males Females Total
(n = 42, 45%) (n = 51, 55%) (n = 44, 47%) (n = 49, 53%) (N = 186)
Demographics
Study Site, n (%)
Soweto 22 (52.4) 29 (56.9) 20 (45.5) 29 (59.2) 100 (53.8)
Klerksdorp 12 (28.6) 7 (13.7) 16 (36.4) 6 (12.2) 41 (22.0)
Cape Town 8 (19.0) 15 (29.4) 8 (18.2) 14 (28.6) 45 (24.2)
Median Age, yrs 23 23 23 24 23
(IQR) (21.0–27.0) (20.0–27.0) (21.0–27.0) (21.0–28.0) (21.0–27.0)
Median BMI 20.9 25.0 20.9 25.5 22.5
(IQR) (18.8–22.3) (21.6–29.7) (19.7–23.2) (22.2–30.4) (20.4–27.0)
Median BMI by Site (IQR)
Soweto 20.3 (18.3–21.0) 23.6 (21.3–26.7) 20.7 (19.8–22.8) 25.2 (22.5–28.6) 22.0 (20.2–25.3)
Klerksdorp 21.2 (19.2–22.2) 21.4 (17.0–27.4) 19.9 (19.3–21.0) 20.9 (18.1–25.5) 20.7 (19.1–22.1)
Cape Town 23.0 (22.3–24.7) 29.5 (26.6–31.6) 28.6 (22.9–31.2) 31.6 (25.1–42.0) 28.0 (23.3–32.4)
Ad5 Titer, n (%)
,18 11 (26.2) 7 (13.7) 4 (9.1) 5 (10.2) 27 (14.5)
18–200 10 (23.8) 16 (31.4) 13 (29.5) 13 (26.5) 52 (28.0)
201–1000 13 (31.0) 20 (39.2) 21 (47.7) 20 (40.8) 74 (39.8)
.1000 8 (19.0) 8 (15.7) 6 (13.6) 11 (22.4) 33 (17.7)
HSV-2 Status, n (%)
Positive 11 (26.2) 31 (60.8) 6 (13.6) 26 (53.1) 74 (39.8)
Negative 31 (73.8) 20 (39.2) 36 (81.8) 23 (46.9) 110 (59.1)
Atypical 0 (0.0) 0 (0.0) 2 (4.5) 0 (0) 2 (1.1)
Heavy Drinkinga, n (%)
Yes 15 (35.7) 3 (5.9) 12 (27.3) 5 (10.2) 35 (18.8)
No 27 (64.3) 48 (94.1) 32 (72.7) 44 (89.8) 151 (81.2)
Abbreviations: IQR, Interquartile Range; BMI, Body Mass Index; Ad5, Adenovirus Type-5; HSV-2, Herpes Simplex Virus Type-2.
aHeavy drinking was self-reported and defined as having more than five drinks per day on at least ten days within six months of the screening and enrollment period.
doi:10.1371/journal.pone.0103446.t001
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determined for the 93 vaccine recipients. The multivariate model
was adjusted for site and age-group. Backward-selection technique
was performed for multivariate variable selection. Hosmer-
Lemeshow Goodness of fit statistics established model diagnostics.
Each two-tailed analysis was determined at the 5% level of
significance. There were no missing data.
Results
Our paper describes a subset of enrolled participants, 93 per
study arm, assessed for immunogenicity by ELISpot analysis.
Baseline Demography of Immunogenicity Participants
Table 1 describes all baseline demographics. Of the 186
immunogenicity participants, 100 (53.7%) were female [51
(51.0% of 100) were vaccine recipients], and 86 (46.3%) were
male [42 (48.8% of 86) were vaccine recipients]. Due to staggered
site initiation, the immunogenicity cohort resided in only three
catchment areas – Soweto (n = 100; 53.8%), Cape Town (n = 45;
24.2%), and Klerksdorp (n = 41; 22.0%). Median age was 23 years
[Interquartile Range (IQR): 21–27]. Most participants were #25
years old (n = 121; 65.1%). Median BMI was 22.5 [IQR: 20.4–
27.0]. Females had a higher median BMI than males (25.3 vs.
20.9; p,0.0001). Most participants had BMI ,25.0 (n = 122;
65.6%). Cape Town had the highest BMI (n = 45; median 28.0
[IQR: 23.3–32.4]), followed by Soweto (n = 100; median 22.0
[IQR: 20.2–25.3]), then Klerksdorp (n = 41; median 20.7 [IQR:
19.1–22.1]). While not shown in Table 1, all mean BMI
comparisons among sites were significant at the 5% level.
The majority of all trial participants was Ad5 antibody positive
(n = 159; 85.5%). The proportion of Ad5 sero-negative males was
higher in vaccine recipients as compared to placebo-recipients (11
vs. 4; p = 0.037). HSV-2 seropositivity at baseline was 39.8%.
Females were more likely to be HSV-2 positive at baseline (57 vs.
17; p,0.0001). Heavy drinkers comprised 18.8% of the cohort:
males were more likely to report heavy drinking than females
(27 vs. 8; p,0.0001).
ELISpot Results for any Clade B or C Antigen and
gag/pol/nef-Specific Responses
As shown in Table 2, 87 (46.8%) of 186 immunogenicity
participants responded to either clade B or clade C antigens (83
[89.2%] of 93 vaccine recipients). All vaccine recipients developed
an IFN-c-secreting T-cell response to either clade B (n = 83;
89.2%) and/or clade C peptides (n = 72; 77.4%; p = 0.17).
Table 2 also shows the distribution of ELISpot responses for
gag/pol/nef-specific antigens. For vaccine recipients, there was a
greater clade B response compared to clade C for antigens gag (74
vs. 48; p = 0.0001) and nef (65 vs. 20; p,0.0001). Clade B and C
responses were similar for the pol-antigen (66 vs. 65; p = 0.87).
Amongst female vaccine recipients, there was a greater B-gag
compared to C-gag response (82.4% vs. 51.0%; p = 0.0008); and
greater B-nef compared to C-nef response (72.6% vs. 19.6%;
p,0.0001).
Multivariate Analyses
In multivariate analysis (Table 3), a statistically significant
predictor for a positive clade C immune response was female sex
[Adjusted Odds Ratio (AOR): 6.478; CI: 1.419–29.570;
p = 0.0159]. Having an overweight/obese BMI [AOR: 0.186;
CI: 0.036–0.965; p = 0.0452] or being a heavy drinker [AOR:
0.270; CI: 0.073–0.990; p = 0.0483] significantly suppressed the
same immune response.
Multivariate analysis showed only one significant antigen-
specific immune response. Table 4 shows female sex is moderately
significant in predicting an increased immune response to clade C-
pol antigens (AOR: 3.182; CI: 1.000–10.120; p = 0.0500). Age,
BMI, Ad5 titer, site, and heavy drinking did not predict a
significant antigen-specific immune response.
Discussion
This is the first investigation of predictors of immune response
to the Phambili vaccine. Our study demonstrates certain
demographic factors affect the immunologic response to clade C
antigens, only. Female sex significantly boosts immune response to
any clade C antigen. Heavy drinking and overweight/obese BMI
significantly inhibit this immune response. Female sex is margin-
ally significant in boosting immune response to the clade C-pol
antigen. Baseline NAd5 titer levels were not a statistically
significant predictor of vaccine immune response.
All 93 vaccine recipients showed immune responses to either
clade B and/or clade C antigens, confirming the Phambili clade B
vaccine had cross-clade reactivity. As previously reported, all clade
C responders also had a clade B response, and gag-specific
responses were highest for clade B, as pol-specific responses were
for clade C [3]. Consistent with the regional clade prevalence,
there were only significant predictors to a clade C immune
response.
This study adds to existing evidence that cross-clade immune
responses are possible. A study conducted in Brazil, Malawi, South
Africa, Thailand, and the USA looked at the cross-reactivity of the
anti-HIV-1 T-cell responses using IFN-c ELISpot assays major
viral clades [18]. It showed that T-cell immune responses
exhibited a substantial degree of cross-reactivity. In South Africa,
95% of the population responded to clade B gag and/or nef
proteins [18].
We did not look at magnitude of immune response (median
SFCs per 106 PBMC), just presence. However, to summarize
previous reporting among responders: any response (678 clade B
vs. 470 clade C), gag (181 vs. 168), pol (292 vs. 250), and nef (168
vs. 145). In responders to both clades, the overall magnitude of
response to the clade B vaccine-matched panel was significantly
higher (p,0.0001) than to clade C PTE panel (p,0.001); the same
pattern held for gag (p = 0.006), pol (p,0.001), and nef (p,0.001)
antigens [3].
The premature halt of Phambili, before the immunogenicity
subset of participants reached third vaccination, potentially
affected the detection of additional and/or stronger predictors.
There may not be enough power to detect additional factors
associated with the Phambili vaccine immune response or yield
stronger associations linked to higher vaccine dosage.
While Step utilized the same vaccine regimen, it was not
conducted in South Africa, and therefore differed from Phambili
with respect to modes of HIV-1 transmission, risk, and clade; and
background Ad5 seroprevalence [19]. Step has not yet been
examined for potential predictors of immune response.
Step was conducted in a region exposed to circulating subtype B
viral strains and included populations of high-risk homosexual
men. Consistent with previous trials and Phambili, the MRK
vaccine in Step was highly immunogenic for inducing HIV-specific
T-cells. IFN-c-secreting HIV-specific T-cells were detected ex-vivo
by validated IFN-c ELISpot and intracellular cytokine staining
assays in 77.0% of Step vaccine recipients, with the majority
recognizing two to three HIV proteins [20]. While Phambili was of
smaller sample size, all vaccine recipients demonstrated immune
response to $1 HIV antigen. In Step, those with lower baseline
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Ad5 titers (#200 units) had higher immune response rates; overall
immune responses did not differ between sexes [20]. Our study
shows baseline NAd5 titer levels were not a statistically significant
predictor of vaccine immune response, despite 80.6% of the
vaccine recipients having detectable baseline Ad5 titer levels;
response rates were higher in females. With dissimilar detectable
Ad5 titer category cut-offs (200 units in Step vs. 18 in Phambili)
there were possibly too few Ad5 seronegative Phambili partici-
pants to detect a relationship between baseline Ad5 titer and
vaccine immune response. However, data from a comparative
study of two MRK-Ad5/HIV-1 vaccine trials conducted in
parallel (Step and HVTN 071) shows pre-existing adenovirus-
specific CD4+ T-cell responses, in addition to NAd5 antibodies,
dampen HIV-specific CD4+ and CD8+ T-cell responses induced
by Ad5-vectored vaccination. Therefore, an Ad5 seronegative
participant may still have high frequencies of pre-immunization
adenovirus-specific CD4+ T-cells, which could impact the number
of epitopes and magnitude of HIV-specific CD8+ T-cell responses
[21].
There is supporting evidence to explain predictors of immune
response found in our study; namely sex, BMI, and drinking.
There are sex differences in immune function. During
reproductive years, women have stronger immune responses than
men, thought to be controlled by differences in blood levels of
gonadal steroid hormones [22]. Estrogen tends to stimulate
immune responses, while testosterone is immunosuppressive [23–
24]. Although estrogen is also present in males, the concentration
is too low to affect immune responses [23].
Evidence explains a relationship between BMI and immune
response. Data suggests levels of leptin, a cytokine-like hormone
linked to the control of food intake and metabolism, is higher in
obese individuals [25]. Leptin can act as a negative signal for
proliferation of T-cells, suppressing the immune system and
increasing incidence and severity of infectious disease [25].
Acute and chronic alcohol exposure exerts multiple effects on
the immune system which may explain suppression of vaccine
immune responses. Alcohol can impede early responses to
infection, decrease production of most white blood cells, impair
navigation ability of neutrophils to sites of injury and infection,
Table 2. Distribution of ELISpot Response per Clade for Any Antigen and Specific Antigens.
Vaccine Arm (n = 93) Placebo Arm (n = 93)
Males (n = 42, 45%) Females (n = 51, 55%) Males (n = 44, 47%) Females (n = 49, 53%) Total (N = 186)
ELISpot Response
Any ELISpot Response, n (%)
Non-Responder 6 (14.3) 4 (7.8) 43 (97.7) 46 (93.9) 99 (53.2)
Respondera 36 (85.7) 47 (92.2) 1 (2.3) 3 (6.1) 87 (46.8)
Clade B ELISpot Response, n (%)
Non-responder 6 (14.3) 4 (7.8) 43 (97.7) 46 (93.9) 99 (53.2)
Respondera 36 (85.7) 47 (92.2) 1 (2.3) 3 (6.1) 87 (46.8)
Clade C ELISpot Response, n (%)
Non-responder 14 (33.3) 7 (13.7) 44 (100.0) 47 (95.9) 112 (60.2)
Respondera 28 (66.7) 44 (86.3) 0 (0.0) 2 (4.1) 74 (39.8)
Clade B-gag ELISpot Response, n (%)
Non-responder 10 (23.8) 9 (17.7) 44 (100.0) 46 (93.9) 109 (58.6)
Respondera 32 (76.2) 42 (82.4) 0 (0.0) 3 (6.1) 77 (41.4)
Clade C-gag ELISpot Response, n (%)
Non-responder 20 (47.6) 25 (49.0) 44 (100.0) 47 (95.9) 136 (73.1)
Respondera 22 (52.4) 26 (51.0) 0 (0.0) 2 (4.1) 50 (26.9)
Clade B-pol ELISpot Response, n (%)
Non-responder 16 (38.1) 11 (21.6) 43 (97.7) 47 (95.9) 117 (62.9)
Respondera 26 (61.9) 40 (78.4) 1 (2.3) 2 (4.1) 69 (37.1)
Clade C-pol ELISpot Response, n (%)
Non-responder 15 (35.7) 13 (25.5) 44 (100.0) 48 (98.0) 120 (64.5)
Respondera 27 (64.3) 38 (74.5) 0 (0.0) 1 (2.0) 69 (35.5)
Clade B-nef ELISpot Response, n (%)
Non-responder 14 (33.3) 14 (27.4) 44 (100.0) 46 (93.9) 118 (63.4)
Respondera 28 (66.7) 37 (72.6) 0 (0.0) 3 (6.1) 68 (36.6)
Clade C-nef ELISpot Response, n (%)
Non-responder 32 (76.2) 41 (80.4) 44 (100.0) 48 (98.0) 165 (88.7)
Respondera 10 (23.8) 10 (19.6) 0 (0.0) 1 (2.0) 21 (11.3)
aResponders were defined as those with antigen-stimulated responses significantly greater than twice their background responses as assessed by a bootstrap test (one-
tailed a 0.05) after adjusting for the multiple antigens within each clade; additionally, background-subtracted responses had to exceed ten SFC per 200 000 PBMC [3].
doi:10.1371/journal.pone.0103446.t002
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and remove and/or alter macrophages and cytokines [23], [26–
28]. People who drink excessively, also tend to neglect their own
nutrition, which can cause the immune system to suffer [29].
In the context of other vaccine studies, the influence of these
predictors has been noted. For example, one study which
vaccinated older adults with Hepatitis A and B vaccines concluded
that sex, BMI, and age significantly influenced both Hepatitis A
and B vaccine immune responses [30]. However another study
conducted with frail, elderly patients, failed to show an associate
between BMI, age, and influenza vaccine antibody response [31].
Additionally, a third study reports that alcoholics have been shown
to have poorer responses to some serotypes of the pneumococcal
vaccine as compared to non-alcoholic controls [32].
There are possible interrelationships among sex, BMI, and
alcohol consumption. Alcohol is related to BMI as it boosts cortisol
levels, a fat-creating hormone; generally reducing fat metabolism
by as much as 73% due to loss of muscle and dehydration [33];
and is correlated with irresponsible and over- eating [29]. Alcohol
itself is high in calories with little nutritional value. All of these
factors promote weight gain [29]. Both increased BMI and alcohol
intake have been shown to affect circulating sex hormones -
adipose (fat) tissue is a source of estrogen biosynthesis and chronic
alcohol exposure can also alter production of estrogen and
testosterone [23], [34].
Our study found a significantly suppressing association between
overweight/obese BMI and clade C immune response, while the
opposite was true for female sex. However, the majority of females
enrolled had BMI above 24.99, defined as overweight, and most
females had higher BMI than their male counterparts. The
boosted vaccine-induced immune response might be due to
estrogen playing an immunomodulatory role. Our Phambili
females were all of reproductive age and adipose tissue further
creates estrogen.
Identification of potential confounders is useful in understand-
ing HIV vaccine immune responses and could help scientists
develop more suitable vaccine candidates for target populations
[35]. The aforementioned explanations for the observations of the
predictors are our speculations, and further investigations are
needed to ascertain how predictors play a role in modifying each
other. A limitation of this study is that it is not possible to gauge the
effect of all possible confounders. Vaccination dosing and
inoculation spacing should be explored in relation to obesity as a
predictor of vaccine immune response. While our data suggests
baseline NAd5 antibodies do not affect immune response, pre-
existing immunity to the vaccine vector might still dampen other
predictors’ HIV-insert specific responses and/or alter efficacy
[20–21].
Our study suggests overweight/obese BMI suppresses immune
responses to the Phambili vaccine regimen, as obesity generally
suppresses the immune system [14], [36], and creates an emerging
concern in the field of vaccine efficacy. A recent meta-analysis
shows a trend toward greater obesity in Southern Africa in the past
three decades [37]. In 2008, 50.0% of men and 60.0% of women
were overweight in South Africa, pointing towards an obesity
pandemic [37]. Stratification by sex and BMI should be
considered in future vaccine efficacy trials to assess the effects on
HIV-1 vaccines by these predictors.
Table 3. Predictors of Phambili Vaccine Immune Response for any Clade C Antigens.
Clade C Univariate Clade C Multivariate
OR (95% CI) p value OR (95% CI) p value
Sex
Male 1.0 1.0
Female 3.14 (1.13–8.75) 0.02 6.48 (1.42–29.57) 0.01
Study Site
Soweto 0.53 (0.19–1.46) 0.22 0.31 (0.09–1.07) 0.06
Others 1.0 1.0
Age Group
#24 years 1.0 1.0
.24 years 1.35 (0.49–3.75) 0.57 1.07 (0.34–3.44) 0.90
BMIa
Normal/Underweight 1.0 1.0
Overweight/Obese 1.03 (0.35–3.01) 0.96 0.19 (0.04–0.97) 0.04
Ad5 Titerb
Positive 0.63 (0.16–2.44) 0.51 0.35 (0.08–1.60) 0.18
Negative 1.0 1.0
Heavy Drinkingc
Yes 0.26 (0.09–0.79) 0.01 0.27 (0.07–0.99) 0.04
No 1.0 1.0
Abbreviations: OR, Odds Ratio; CI, Confidence Interval; BMI, Body Mass Index; Ad5, Adenovirus Type-5.
aBMI was categorized as underweight (,18.5), normal (18.5–24.9), overweight (25.0–29.9), and obese (.29.9); bAd5 titer levels were defined as positive (.18 units) and
negative (#18 units); and cHeavy drinking was self-reported and defined as having more than five drinks per day on at least ten days within six months of the screening
and enrollment period.
All categorical references are valued as 1.0. Bold values represent statistically significant data.
doi:10.1371/journal.pone.0103446.t003
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